BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bellinvia S, Cummings JRF, Ardern-jones MR, Edwards CJ. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. BioDrugs 2019;33:241-53. [DOI: 10.1007/s40259-019-00355-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Horta-baas G. Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake? PROM 2022;Volume 13:79-95. [DOI: 10.2147/prom.s256715] [Reference Citation Analysis]
2 Cantini F, Benucci M, Li Gobbi F, Franchi G, Niccoli L. Biosimilars for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology 2019;15:1195-203. [DOI: 10.1080/1744666x.2020.1682553] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Bellinvia S, Edwards CJ. Explaining biosimilars and how reverse engineering plays a critical role in their development. Expert Opin Drug Discov 2020;15:1283-9. [PMID: 32717155 DOI: 10.1080/17460441.2020.1796627] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Gisondi P, Geat D, Conti A, Dapavo P, Piaserico S, De Simone C, Bianchi L, Costanzo A, Malagoli P, Malara G, Micali G, Naldi L, Offidani A, Patrizi A, Prignano F, Parodi A, Rongioletti F, Calzavara-pinton P, Girolomoni G. TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Review of Clinical Immunology 2020;16:591-8. [DOI: 10.1080/1744666x.2020.1771182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Sota J, Gentileschi S, Vitale A, Gaggiano C, De Bartolo G, Bianco MT, Frediani B, Tosi GM, Cantarini L, Fabiani C. Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience. Asia Pac J Ophthalmol (Phila) 2021;10:360-5. [PMID: 33756492 DOI: 10.1097/APO.0000000000000380] [Reference Citation Analysis]
6 Demirkan FG, Ulu K, Öztürk K, Karadağ ŞG, Özdel S, Sönmez HE, Çakmak F, Demir F, Sözeri B, Aktay Ayaz N. Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. Expert Opin Biol Ther 2021;:1-6. [PMID: 34730483 DOI: 10.1080/14712598.2021.2002296] [Reference Citation Analysis]
7 Li N, Wang Y, Wang X, Sun N, Gong YH. Pathway network of pyroptosis and its potential inhibitors in acute kidney injury. Pharmacol Res 2021;175:106033. [PMID: 34915124 DOI: 10.1016/j.phrs.2021.106033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Fusaro E, Durez P, Wohlrab J, Lee S, SangWook Yoon, Marotte H. An update on the adalimumab biosimilar landscape following the approval of the first high-concentration biosimilar. Immunotherapy 2021. [PMID: 34865524 DOI: 10.2217/imt-2021-0271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs 2022. [PMID: 35596890 DOI: 10.1007/s40259-022-00533-x] [Reference Citation Analysis]
10 Shin YK, Han WY, Kim SJ, Kim KW, Roh JW, Lee JB, Oh JS, Astier A. Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17. Adv Ther 2021;38:5609-22. [PMID: 34618346 DOI: 10.1007/s12325-021-01929-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H. Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals (Basel) 2021;14:189. [PMID: 33669108 DOI: 10.3390/ph14030189] [Reference Citation Analysis]
12 Davidson A, Brimhall D, Kay J, Keystone E, Lee SJ, Kim SH, Bae YJ, Choi EJ, Furst DE. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. Br J Clin Pharmacol 2021. [PMID: 33822406 DOI: 10.1111/bcp.14850] [Reference Citation Analysis]
13 Edwards CJ, Bellinvia S. Biosimilars. Lupus 2020;29:525-32. [PMID: 32188301 DOI: 10.1177/0961203320910797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H. Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals 2021;69:30-7. [PMID: 33454195 DOI: 10.1016/j.biologicals.2020.12.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Gherghescu I, Delgado-Charro MB. The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. Pharmaceutics 2020;13:48. [PMID: 33396369 DOI: 10.3390/pharmaceutics13010048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart AH, Alavi A. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors? Am J Clin Dermatol 2021;22:139-47. [PMID: 33398848 DOI: 10.1007/s40257-020-00579-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]